ALR Technologies SG（ALRT.F）株式概要データ管理会社であるALR Technologies SG Ltd.は、人と動物の糖尿病ケア管理ソリューションを提供しています。 詳細ALRT.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析キャッシュランウェイが1年未満である 意味のある時価総額がありません ( $10M )過去5年間で収益は年間24.4%減少しました。 マイナスの株主資本 +2 さらなるリスクすべてのリスクチェックを見るALRT.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.015該当なし内在価値ディスカウントEst. Revenue$PastFuture-22m26k2016201920222025202620282031Revenue US$1.7Earnings US$0.2AdvancedSet Fair ValueView all narrativesALR Technologies SG Ltd. 競合他社Sintx TechnologiesSymbol: NasdaqCM:SINTMarket cap: US$10.3mScientific IndustriesSymbol: OTCPK:SCNDMarket cap: US$9.1mNexalin TechnologySymbol: NasdaqCM:NXLMarket cap: US$7.8mBiomericaSymbol: NasdaqCM:BMRAMarket cap: US$7.7m価格と性能株価の高値、安値、推移の概要ALR Technologies SG過去の株価現在の株価US$0.01552週高値US$0.02552週安値US$0.0033ベータ2.311ヶ月の変化1.01%3ヶ月変化6.19%1年変化50.00%3年間の変化-58.33%5年間の変化-70.59%IPOからの変化-83.33%最新ニュースお知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.最新情報をもっと見るRecent updatesお知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.株主還元ALRT.FUS Medical EquipmentUS 市場7D-12.2%2.0%1.1%1Y50.0%-17.9%28.7%株主還元を見る業界別リターン: ALRT.F過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: ALRT.F過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is ALRT.F's price volatile compared to industry and market?ALRT.F volatilityALRT.F Average Weekly Movement51.6%Medical Equipment Industry Average Movement8.8%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: ALRT.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ALRT.Fの weekly volatility ( 52% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19877Sidney S. Chanwww.alrt.comデータマネジメント会社であるALR Technologies SG Ltd.は、人と動物の糖尿病ケアマネジメントソリューションを提供しています。同社は、血糖測定器や持続グルコースモニタリング装置から直接データを収集する糖尿病管理システム、検査報告書とFDA認可のインスリン投与調整プログラムの間で治療の成功を追跡する予測A1Cアルゴリズムを含む糖尿病ケア、ALRT糖尿病ソリューションを提供しています。同社はまた、獣医師がインスリン治療の有効性を判断し、コンパニオンアニマルの適切な投与量と投与頻度を特定するのに役立つソリューション、GluCurve Pet CGMも提供している。同社は、米国、ブラジル、英国、欧州連合、および国際的な販売代理店を通じて製品を直接販売している。同社は1987年に設立され、シンガポールを拠点としている。もっと見るALR Technologies SG Ltd. 基礎のまとめALR Technologies SG の収益と売上を時価総額と比較するとどうか。ALRT.F 基礎統計学時価総額US$9.68m収益（TTM）-US$22.06m売上高(TTM)n/a0.0xP/Sレシオ-0.4xPER（株価収益率ALRT.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ALRT.F 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$22.06m収益-US$22.06m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.034グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-81.0%ALRT.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 06:31終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ALR Technologies SG Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Juan NobleTaglich Brothers, Inc.
お知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.
お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.
お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.
お知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.
お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.
お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.
